Work

Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia.

Year: 2017

Type: article

Source: Journal of Nuclear Medicine

Authors: Joseph G. Jurcic, Moshe Levy, Jae H. Park, Farhad Ravandi, Alexander E. Perl, John M. Pagel, Ben J. Smith, Johnnie J. Orozco, Elihu H. Estey, Hagop M. Kantarjian, Dragan Cicic, David A. Scheinberg

Institutions: Columbia University Irving Medical Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pennsylvania, Swedish Medical Center, Johns Hopkins University, Fred Hutch Cancer Center, Actinium Pharmaceuticals (United States)

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2620489408

FWCI: 0.947

Cites:

Cited by: 8

Related to: 20